Jump to content

Alazocine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Trappist the monk (talk | contribs) at 15:25, 22 May 2016 (→top: cs1|2 maint: multiple authors/editors fixes; using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Alazocine
Clinical data
Routes of
administration		?
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • (2R,6R,11R)-6,11-Dimethyl-3-prop-2-en-1-yl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.162.264 Edit this at Wikidata
Chemical and physical data
FormulaC17H23NO
Molar mass257.37 g/mol g·mol−1
3D model (JSmol)
  • C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C)C)C=C(C=C3)O
  • InChI=1S/C17H23NO/c1-4-8-18-9-7-17(3)12(2)16(18)10-13-5-6-14(19)11-15(13)17/h4-6,11-12,16,19H,1,7-10H2,2-3H3/t12-,16+,17+/m0/s1 checkY
  • Key:LGQCVMYAEFTEFN-JCURWCKSSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Alazocine ((-)-SKF-10,047), or (-)-N-allylnormetazocine ((-)-ANMC), was the first drug discovered to act as a σ1 receptor agonist (Ki = 24 nM).[1][2][3] It has no significant affinity for the σ2 receptor.[3] Alazocine also acts as a κ-opioid receptor partial agonist (Ki = 0.4 nM; EC50 = 24 nM; Emax = 66%),[4] and to a much lesser extent, as an NMDA receptor antagonist (Ki = 587 nM).[3][5]

See also

References

  1. ^ Iwamoto ET (February 1981). "Pharmacologic effects of N-allylnormetazocine (SKF-10047)". NIDA Research Monograph. 34: 82–8. PMID 6783955.
  2. ^ Shearman GT, Herz A (August 1982). "Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat". European Journal of Pharmacology. 82 (3–4): 167–72. doi:10.1016/0014-2999(82)90506-4. PMID 6290235.
  3. ^ a b c Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (March 1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research. 821 (2): 516–9. doi:10.1016/S0006-8993(99)01125-7. PMID 10064839.
  4. ^ Gharagozlou, Parham; Hashemi, Ezzat; DeLorey, TimothyM; Clark, J David; Lameh, Jelveh (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology. 6 (1): 3. doi:10.1186/1471-2210-6-3. ISSN 1471-2210.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology. 6 (1): 3. doi:10.1186/1471-2210-6-3. PMC 1403760. PMID 16433932.{{cite journal}}: CS1 maint: unflagged free DOI (link)


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Alazocine&oldid=721544784"